<DOC>
	<DOC>NCT02118766</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.</brief_summary>
	<brief_title>Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Males or females 2 years and older Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka Has AD involvement â‰¥ 5% Treatable %BSA (excluding the scalp) Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1 All female subjects of childbearing potential must use acceptable methods of contraception from the Screening Visit continuously until 30 days after stopping study drug As determined by the study doctor, a medical history that may interfere with study objectives Unstable AD or any consistent requirement for high potency topical corticosteroids History of use of biologic therapy (including intravenous immunoglobulin) Recent or anticipated concomitant use of systemic or topical therapies that might alter the course of AD Recent or current participation in another research study Females who are breastfeeding, pregnant, or with plans to get pregnant during the participation in the study Participation in a previous AN2728 clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>atopic dermatitis</keyword>
</DOC>